Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival

Siamak Daneshmand, Marcus L. Quek, Ed Lin, Charlotte Lee, Richard J Cote, Debra Hawes, Jie Cai, Susan Groshen, Gary Lieskovsky, Donald G. Skinner, Amy S. Lee, Jacek Pinski

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Chemotherapy resistance is a significant contributor to treatment failure and death in men with hormone-refractory prostate cancer. One unexplored mechanism for drug resistance is the induction of stress response proteins referred to as the glucose-regulated proteins (GRPs). We sought to determine the level of expression of GRP78, the best characterized GRP in lymph node-positive prostate cancer. Archived, paraffin-embedded, radical prostatectomy specimens were obtained from 153 patients with lymph node-positive prostate cancer (stage D1). The level of GRP78 expression was determined by immunohistochemistry. We assessed the expression and specificity of GRP78 immunoreactivity in benign prostatic tissue, prostate cancer, and lymph node metastasis. We correlated the intensity of immunopositivity with prostate cancer recurrence and survival. Whereas immunohistochemical staining demonstrated that all prostate tissue was immunoreactive for GRP78, the intensity of expression was markedly higher in the primary tumor compared with areas of benign epithelium. GRP78 expression was also evident in lymph node metastases although less intensely than in the primary tumor. Patients with strong GRP78 immunoreactivity in the primary tumor are at higher risk for clinical recurrence (relative risk = 2.0, P = .019) and death (relative risk = 1.8, P = .024) than patients with weak GRP78 expression. This finding confirms that GRP78 protein expression is significantly higher in prostate cancer than in benign prostatic tissue. The intensity of expression is significantly associated with survival and clinical recurrence. GRP78 has considerable potential not only as a prognostic indicator but also as a potential therapeutic target.

Original languageEnglish
Pages (from-to)1547-1552
Number of pages6
JournalHuman Pathology
Volume38
Issue number10
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Recurrence
Survival
Lymph Nodes
Neoplasm Metastasis
Neoplasms
Prostatectomy
Heat-Shock Proteins
Treatment Failure
Drug Resistance
Paraffin
glucose-regulated proteins
Prostate
Epithelium
Immunohistochemistry
Hormones
Staining and Labeling
Drug Therapy
Proteins
Therapeutics

Keywords

  • Glucose-regulated protein (GRP78)
  • Prognosis
  • Prostate cancer
  • Radical prostatectomy
  • Unfolded protein response

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. / Daneshmand, Siamak; Quek, Marcus L.; Lin, Ed; Lee, Charlotte; Cote, Richard J; Hawes, Debra; Cai, Jie; Groshen, Susan; Lieskovsky, Gary; Skinner, Donald G.; Lee, Amy S.; Pinski, Jacek.

In: Human Pathology, Vol. 38, No. 10, 01.10.2007, p. 1547-1552.

Research output: Contribution to journalArticle

Daneshmand, S, Quek, ML, Lin, E, Lee, C, Cote, RJ, Hawes, D, Cai, J, Groshen, S, Lieskovsky, G, Skinner, DG, Lee, AS & Pinski, J 2007, 'Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival', Human Pathology, vol. 38, no. 10, pp. 1547-1552. https://doi.org/10.1016/j.humpath.2007.03.014
Daneshmand, Siamak ; Quek, Marcus L. ; Lin, Ed ; Lee, Charlotte ; Cote, Richard J ; Hawes, Debra ; Cai, Jie ; Groshen, Susan ; Lieskovsky, Gary ; Skinner, Donald G. ; Lee, Amy S. ; Pinski, Jacek. / Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. In: Human Pathology. 2007 ; Vol. 38, No. 10. pp. 1547-1552.
@article{708cc41a8ee6483992b8c3e0982335a2,
title = "Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival",
abstract = "Chemotherapy resistance is a significant contributor to treatment failure and death in men with hormone-refractory prostate cancer. One unexplored mechanism for drug resistance is the induction of stress response proteins referred to as the glucose-regulated proteins (GRPs). We sought to determine the level of expression of GRP78, the best characterized GRP in lymph node-positive prostate cancer. Archived, paraffin-embedded, radical prostatectomy specimens were obtained from 153 patients with lymph node-positive prostate cancer (stage D1). The level of GRP78 expression was determined by immunohistochemistry. We assessed the expression and specificity of GRP78 immunoreactivity in benign prostatic tissue, prostate cancer, and lymph node metastasis. We correlated the intensity of immunopositivity with prostate cancer recurrence and survival. Whereas immunohistochemical staining demonstrated that all prostate tissue was immunoreactive for GRP78, the intensity of expression was markedly higher in the primary tumor compared with areas of benign epithelium. GRP78 expression was also evident in lymph node metastases although less intensely than in the primary tumor. Patients with strong GRP78 immunoreactivity in the primary tumor are at higher risk for clinical recurrence (relative risk = 2.0, P = .019) and death (relative risk = 1.8, P = .024) than patients with weak GRP78 expression. This finding confirms that GRP78 protein expression is significantly higher in prostate cancer than in benign prostatic tissue. The intensity of expression is significantly associated with survival and clinical recurrence. GRP78 has considerable potential not only as a prognostic indicator but also as a potential therapeutic target.",
keywords = "Glucose-regulated protein (GRP78), Prognosis, Prostate cancer, Radical prostatectomy, Unfolded protein response",
author = "Siamak Daneshmand and Quek, {Marcus L.} and Ed Lin and Charlotte Lee and Cote, {Richard J} and Debra Hawes and Jie Cai and Susan Groshen and Gary Lieskovsky and Skinner, {Donald G.} and Lee, {Amy S.} and Jacek Pinski",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.humpath.2007.03.014",
language = "English",
volume = "38",
pages = "1547--1552",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival

AU - Daneshmand, Siamak

AU - Quek, Marcus L.

AU - Lin, Ed

AU - Lee, Charlotte

AU - Cote, Richard J

AU - Hawes, Debra

AU - Cai, Jie

AU - Groshen, Susan

AU - Lieskovsky, Gary

AU - Skinner, Donald G.

AU - Lee, Amy S.

AU - Pinski, Jacek

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Chemotherapy resistance is a significant contributor to treatment failure and death in men with hormone-refractory prostate cancer. One unexplored mechanism for drug resistance is the induction of stress response proteins referred to as the glucose-regulated proteins (GRPs). We sought to determine the level of expression of GRP78, the best characterized GRP in lymph node-positive prostate cancer. Archived, paraffin-embedded, radical prostatectomy specimens were obtained from 153 patients with lymph node-positive prostate cancer (stage D1). The level of GRP78 expression was determined by immunohistochemistry. We assessed the expression and specificity of GRP78 immunoreactivity in benign prostatic tissue, prostate cancer, and lymph node metastasis. We correlated the intensity of immunopositivity with prostate cancer recurrence and survival. Whereas immunohistochemical staining demonstrated that all prostate tissue was immunoreactive for GRP78, the intensity of expression was markedly higher in the primary tumor compared with areas of benign epithelium. GRP78 expression was also evident in lymph node metastases although less intensely than in the primary tumor. Patients with strong GRP78 immunoreactivity in the primary tumor are at higher risk for clinical recurrence (relative risk = 2.0, P = .019) and death (relative risk = 1.8, P = .024) than patients with weak GRP78 expression. This finding confirms that GRP78 protein expression is significantly higher in prostate cancer than in benign prostatic tissue. The intensity of expression is significantly associated with survival and clinical recurrence. GRP78 has considerable potential not only as a prognostic indicator but also as a potential therapeutic target.

AB - Chemotherapy resistance is a significant contributor to treatment failure and death in men with hormone-refractory prostate cancer. One unexplored mechanism for drug resistance is the induction of stress response proteins referred to as the glucose-regulated proteins (GRPs). We sought to determine the level of expression of GRP78, the best characterized GRP in lymph node-positive prostate cancer. Archived, paraffin-embedded, radical prostatectomy specimens were obtained from 153 patients with lymph node-positive prostate cancer (stage D1). The level of GRP78 expression was determined by immunohistochemistry. We assessed the expression and specificity of GRP78 immunoreactivity in benign prostatic tissue, prostate cancer, and lymph node metastasis. We correlated the intensity of immunopositivity with prostate cancer recurrence and survival. Whereas immunohistochemical staining demonstrated that all prostate tissue was immunoreactive for GRP78, the intensity of expression was markedly higher in the primary tumor compared with areas of benign epithelium. GRP78 expression was also evident in lymph node metastases although less intensely than in the primary tumor. Patients with strong GRP78 immunoreactivity in the primary tumor are at higher risk for clinical recurrence (relative risk = 2.0, P = .019) and death (relative risk = 1.8, P = .024) than patients with weak GRP78 expression. This finding confirms that GRP78 protein expression is significantly higher in prostate cancer than in benign prostatic tissue. The intensity of expression is significantly associated with survival and clinical recurrence. GRP78 has considerable potential not only as a prognostic indicator but also as a potential therapeutic target.

KW - Glucose-regulated protein (GRP78)

KW - Prognosis

KW - Prostate cancer

KW - Radical prostatectomy

KW - Unfolded protein response

UR - http://www.scopus.com/inward/record.url?scp=34548671627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548671627&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2007.03.014

DO - 10.1016/j.humpath.2007.03.014

M3 - Article

C2 - 17640713

AN - SCOPUS:34548671627

VL - 38

SP - 1547

EP - 1552

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 10

ER -